These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 8722487)

  • 1. Bioequivalence and generic prescribing: an industrial view.
    Pidgen A
    J Pharm Pharmacol; 1996 Jan; 48(1):11-6. PubMed ID: 8722487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence and generic prescribing: a pharmacy view.
    Calvert RT
    J Pharm Pharmacol; 1996 Jan; 48(1):9-10. PubMed ID: 8722486
    [No Abstract]   [Full Text] [Related]  

  • 3. Bioequivalence and other unresolved issues in generic drug substitution.
    Meredith P
    Clin Ther; 2003 Nov; 25(11):2875-90. PubMed ID: 14693311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current regulatory approaches of bioequivalence testing.
    Karalis V; Macheras P
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence/bioavailability retention samples.
    Ransom C
    Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218
    [No Abstract]   [Full Text] [Related]  

  • 8. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
    Kuribayashi R; Takishita T; Mikami K
    J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 13. Supreme Court decision may have major impact on drug industry.
    Spurgeon D
    CMAJ; 1993 Feb; 148(4):629-31. PubMed ID: 8431828
    [No Abstract]   [Full Text] [Related]  

  • 14. Bioequivalence studies for levothyroxine.
    Bolton S
    AAPS J; 2005 Mar; 7(1):E47-53. PubMed ID: 16146349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Bioequivalence a Sufficient Measure of Equivalence?
    Holman A
    J Leg Med; 2019; 39(3):247-261. PubMed ID: 31626574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.
    Tothfalusi L; Endrenyi L; Arieta AG
    Clin Pharmacokinet; 2009; 48(11):725-43. PubMed ID: 19817502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Input to the discussion on proposed regulation of prescription pharmacies].
    Agência Nacional de Vigilância Sanitária - Anvisa
    Rev Saude Publica; 2005 Aug; 39(4):691-4. PubMed ID: 16113925
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
    Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
    Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the bioavailability and bioequivalence of generic medications.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the safety of generic drugs.
    Dighe SV
    Transplant Proc; 1999 May; 31(3A Suppl):23S-24S. PubMed ID: 10330955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.